Trial Outcomes & Findings for Electronic Strategies for Tailored Exercise to Prevent FallS (NCT NCT04993781)

NCT ID: NCT04993781

Last Updated: 2026-07-08

Results Overview

To determine the effect of the eSTEPS intervention on all falls per 100 patient years

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

11945 participants

Primary outcome timeframe

Up to 23 months

Results posted on

2026-07-08

Participant Flow

Unit of analysis: Practice sites

Participant milestones

Participant milestones
Measure
eSTEPS Clinical Decision Support
Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
Usual Care
Usual primary care practices regarding exercise-related fall prevention planning
Overall Study
STARTED
5681 12
6264 12
Overall Study
COMPLETED
5221 11
5841 11
Overall Study
NOT COMPLETED
460 1
423 1

Reasons for withdrawal

Reasons for withdrawal
Measure
eSTEPS Clinical Decision Support
Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
Usual Care
Usual primary care practices regarding exercise-related fall prevention planning
Overall Study
Death
433
402
Overall Study
Lost to Follow-up
27
21

Baseline Characteristics

The rows are showing the data broken down by sex (male or female)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
eSTEPS Clinical Decision Support
n=5681 Participants
Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
Usual Care
n=6264 Participants
Usual primary care practices regarding exercise-related fall prevention planning
Total
n=11945 Participants
Total of all reporting groups
Age, Continuous
76.7 Years
STANDARD_DEVIATION 7.5 • n=5681 Participants
77.3 Years
STANDARD_DEVIATION 7.4 • n=6264 Participants
77.1 Years
STANDARD_DEVIATION 7.4 • n=11945 Participants
Sex: Female, Male
Female
3853 Participants
n=5681 Participants • The rows are showing the data broken down by sex (male or female)
4191 Participants
n=6264 Participants • The rows are showing the data broken down by sex (male or female)
8044 Participants
n=11945 Participants • The rows are showing the data broken down by sex (male or female)
Sex: Female, Male
Male
1828 Participants
n=5681 Participants • The rows are showing the data broken down by sex (male or female)
2073 Participants
n=6264 Participants • The rows are showing the data broken down by sex (male or female)
3901 Participants
n=11945 Participants • The rows are showing the data broken down by sex (male or female)
Ethnicity (NIH/OMB)
Hispanic or Latino
480 Participants
n=5681 Participants
567 Participants
n=6264 Participants
1047 Participants
n=11945 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4987 Participants
n=5681 Participants
5436 Participants
n=6264 Participants
10423 Participants
n=11945 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
214 Participants
n=5681 Participants
261 Participants
n=6264 Participants
475 Participants
n=11945 Participants
Race/Ethnicity, Customized
White
4436 Participants
n=5681 Participants
4992 Participants
n=6264 Participants
9428 Participants
n=11945 Participants
Race/Ethnicity, Customized
Black/African American
585 Participants
n=5681 Participants
360 Participants
n=6264 Participants
945 Participants
n=11945 Participants
Race/Ethnicity, Customized
Other
131 Participants
n=5681 Participants
299 Participants
n=6264 Participants
430 Participants
n=11945 Participants
Race/Ethnicity, Customized
Missing
529 Participants
n=5681 Participants
613 Participants
n=6264 Participants
1142 Participants
n=11945 Participants
Falls Self-efficacy (fear of falling)
8.6 Score
STANDARD_DEVIATION 1.6 • n=351 Participants • This measures was collected from a pre-planned subsample of participants, so there are fewer participants than in the overall trial
8.8 Score
STANDARD_DEVIATION 1.4 • n=308 Participants • This measures was collected from a pre-planned subsample of participants, so there are fewer participants than in the overall trial
8.7 Score
STANDARD_DEVIATION 1.5 • n=659 Participants • This measures was collected from a pre-planned subsample of participants, so there are fewer participants than in the overall trial
Self-efficacy for exercise
6.9 Score
STANDARD_DEVIATION 2.4 • n=349 Participants • This measures was collected from a pre-planned subsample of participants, so there are fewer participants than in the overall trial
7.3 Score
STANDARD_DEVIATION 2.2 • n=307 Participants • This measures was collected from a pre-planned subsample of participants, so there are fewer participants than in the overall trial
7.1 Score
STANDARD_DEVIATION 2.3 • n=656 Participants • This measures was collected from a pre-planned subsample of participants, so there are fewer participants than in the overall trial

PRIMARY outcome

Timeframe: Up to 23 months

To determine the effect of the eSTEPS intervention on all falls per 100 patient years

Outcome measures

Outcome measures
Measure
eSTEPS Intervention
n=5681 Participants
Intervention group that was provided access to the eSTEPS fall exercise prevention clinical decision support tool
Control Group
n=6264 Participants
Received usual care
To Determine the Effect of the eSTEPS Intervention on the Rate of Falls
19.3 Falls per 100 person years
Interval 18.6 to 20.1
21.2 Falls per 100 person years
Interval 20.2 to 22.1

SECONDARY outcome

Timeframe: Change from initial assessment to 6 months

Population: This outcome was collected on a pre-planned randomly selected subgroup of participants who provided consent for telephone interviews

Falls self-efficacy (fear of falling) will be measured using the Modified Falls Efficacy Scale (mFES). This scale assesses confidence with completing a list of activities without falling and contains 14 items each measured on a scale of 0 to 10. 0 means "not confident at all", 5 means "fairly confident", and 10 means "completely confident." he total score is the average of all of the item scores and ranges from zero to ten. A higher score reflects more confidence and less fear of falling. Participants are classified as either fearful (MFES score \< 8) or not fearful (MFES greater than or equal to 8). The total score range is 0 to 10.

Outcome measures

Outcome measures
Measure
eSTEPS Intervention
n=300 Participants
Intervention group that was provided access to the eSTEPS fall exercise prevention clinical decision support tool
Control Group
n=273 Participants
Received usual care
To Determine the Effect of the eSTEPS Intervention on Falls Self-efficacy (Fear of Falling)
0.0 Change in Mean Score
Standard Deviation 1.1
-0.04 Change in Mean Score
Standard Deviation 0.88

SECONDARY outcome

Timeframe: Change from initial visit to 6 months

Population: This outcome was collected on a pre-planned randomly selected subgroup of participants who provided consent for telephone interviews

Self-efficacy for exercise will be measured using the Self-Efficacy for Exercise (SEE) Scale. This scale consists of nine situations that may affect participation in exercise and ask participants to describe their current level of confidence that they could exercise 3 times a week for 20 minutes each time. 0 means "not confident", 5 means "fairly confident", and 10 means "very confident." The total score for the SEE scale is calculated by taking the numerical ratings for each statement and dividing by number of responses. The score indicates the strength of self-efficacy for exercise expectations. The higher the average score, the greater the participant's self-efficacy for exercise. The total score range is 0 to 10.

Outcome measures

Outcome measures
Measure
eSTEPS Intervention
n=300 Participants
Intervention group that was provided access to the eSTEPS fall exercise prevention clinical decision support tool
Control Group
n=273 Participants
Received usual care
To Determine the Effect of the eSTEPS Intervention on Self-efficacy for Exercise
-0.15 Change in Mean score
Standard Deviation 2.1
-0.35 Change in Mean score
Standard Deviation 2

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 23 months

To explore the effect of the esteps intervention on the rate of death (mortality) in the intervention versus control groups

Outcome measures

Outcome measures
Measure
eSTEPS Intervention
n=5681 Participants
Intervention group that was provided access to the eSTEPS fall exercise prevention clinical decision support tool
Control Group
n=6264 Participants
Received usual care
To Explore the Effect of the eSTEPS Intervention on Death
5.9 Death per 100 person years
Interval 5.0 to 7.0
5.6 Death per 100 person years
Interval 5.1 to 6.1

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 23 months

To determine the effect of the eSTEPS intervention on the rate of fall injuries calculated as fall-related injuries per 100 person years

Outcome measures

Outcome measures
Measure
eSTEPS Intervention
n=5681 Participants
Intervention group that was provided access to the eSTEPS fall exercise prevention clinical decision support tool
Control Group
n=6264 Participants
Received usual care
To Determine the Effect of the eSTEPS Intervention the Rate of Fall-related Injuries
15.7 Fall-related injuries /100 person years
Interval 15.0 to 16.5
16.7 Fall-related injuries /100 person years
Interval 16.1 to 17.4

Adverse Events

eSTEPS Clinical Decision Support

Serious events: 1767 serious events
Other events: 0 other events
Deaths: 433 deaths

Usual Care

Serious events: 1787 serious events
Other events: 0 other events
Deaths: 402 deaths

Serious adverse events

Serious adverse events
Measure
eSTEPS Clinical Decision Support
n=5681 participants at risk
Use of clinical decision support to assist in exercise-related fall prevention care planning will be compared to usual care.
Usual Care
n=6264 participants at risk
Usual primary care practices regarding exercise-related fall prevention planning
General disorders
Hospitalization and/or death
31.1%
1767/5681 • Number of events 4130 • Baseline to 23 months
In this pragmatic trial, only serious adverse were monitored
28.5%
1787/6264 • Number of events 4073 • Baseline to 23 months
In this pragmatic trial, only serious adverse were monitored

Other adverse events

Adverse event data not reported

Additional Information

Nancy Latham

Brigham and Women's Hosptial

Phone: 617-999-9195

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place